Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Alliance Pharmaceutical (NasdaqNM:ALLP)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug 31Price hit new 52-week low ($1.17)
Location
3040 Science Park Road
San Diego, CA 92121
Phone: (858) 410-5200
Fax: (858) 410-5201
Email: corpcom@allp.com
Employees (last reported count): 234
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 16%
·Institutional: 31% (37% of float)
(163 institutions)
·Net Inst. Selling: 850.0K shares (+5.83%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Alliance Pharmaceutical Corp. is a pharmaceutical research and development company that focuses on developing scientific discoveries into medical products and licensing these products to multinational pharmaceutical companies in exchange for fixed payments and royalty or profit sharing payments. To date, the Company has developed three products through initial clinical (human) trials and is in, or has completed, pivotal clinical trials for these products. The products are Oxygent, an intravascular oxygen carrier to temporarily augment oxygen delivery in surgical and other patients at risk of acute tissue hypoxia (oxygen deficiency); Liquivent, an intrapulmonary agent for use in reducing a patient's exposure to the harmful effects of conventional mechanical ventilation; and Imavist (formerly named Imagent), an intravenous contrast agent for enhancement of ultrasound images to assess cardiac function and organ lesions and to detect blood flow abnormalities.
More from Market Guide: Expanded Business Description

Financial Summary
Alliance Pharmaceutical is a pharmaceutical research and development company focused on developing scientific discoveries into potential medical products. For the nine months ended 3/31/01, revenues decreased 90% to $1.6 million. Net loss increased 34% to $46.9 million. Revenues reflect the absence of sales of the PulmoSpheres technology to Inhale Therapeutic Systems. Higher loss reflects payments to outside researchers for clinical trials.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Duane Roth, 50
CEO and Chairman
$513K
Theodore Roth, 49
Pres and COO
361K
Harold DeLong, 52
Exec. VP, Bus. Devel.
257K
Artemios Vassos, M.D., 53
Exec. VP and CSO
401K
David Klein, Ph.D., 67
Sr. VP, Pharmaceutical Devel.
--  
Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ALLPAs of 31-Aug-2001
Price and Volume
52-Week Low
on 31-Aug-2001
$1.17 
Recent Price$1.20 
52-Week High
on 14-Sep-2000
$17.75 
Beta0.71 
Daily Volume (3-month avg)344.0K
Daily Volume (10-day avg)328.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-92.7%
52-Week Change
relative to S&P500
-90.2%
Share-Related Items
Market Capitalization$59.4M
Shares Outstanding49.5M
Float41.6M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.12 
Earnings (ttm)-$1.21 
Earnings (mrq)-$0.35 
Sales (ttm)$0.04 
Cash (mrq)$0.28 
Valuation Ratios
Price/Book (mrq)9.76 
Price/EarningsN/A 
Price/Sales (ttm)31.41 
Income Statements
Sales (ttm)$1.84M
EBITDA (ttm)-$60.5M
Income available to common (ttm)-$58.5M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsJune 30
Most recent quarter31-Mar-2001
Management Effectiveness
Return on Assets (ttm)-82.63%
Return on Equity (ttm)-248.69%
Financial Strength
Current Ratio (mrq)1.07 
Debt/Equity (mrq)5.50 
Total Cash (mrq)$13.8M
Short Interest
As of 8-Aug-2001
Shares Short1.29M
Percent of Float3.1%
Shares Short
(Prior Month)
1.40M
Short Ratio2.47 
Daily Volume523.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.